Stifel raised the firm’s price target on Palvella Therapeutics (PVLA) to $87 from $80 and keeps a Buy rating on the shares. The firm notes the company disclosed its newest QTORIN-leveraged program – pitavastatin for disseminated superficial actinic prokeratosis/DSAP, a chronic and debilitating, precancerous rare genetic skin condition with the hallmarks of Palvella’s optimal disease targets. The condition has a clear pathogenesis, scientific validation, unmet need, and a defined population. Stifel is impressed with the speed at which Palvella is layering in value-enhancing programs to build the first dermatology-based orphan drug company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella price target raised to $200 from $120 at Cantor Fitzgerald
- Palvella Therapeutics Unveils QTORIN™ Pitavastatin for DSAP
- Ligand price target raised to $250 from $190 at Oppenheimer
- Palvella Therapeutics’ Phase 2 Study on PTX-022: A Potential Game-Changer for Cutaneous Venous Malformations
- Palvella Therapeutics Advances Phase 3 Study on QTORIN Gel for Rare Disease